PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRT-811 overview

PRT-811 is under development for treatment of advanced solid tumors including CNS lymphoma, high grade glioma, glioblastoma multiforme, uveal melanoma and myelofibrosis. It is administered through oral route. The drug candidate acts by targeting the protein arginine N methyltransferase 5 (PRMT5).

Prelude Therapeutics overview

Prelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States.

For a complete picture of PRT-811’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.